ClinicalTrials.gg
RecruitingNCT06782607Updated Nov 17, 2026

Clinical Impact of a Multiplex Rapid Diagnostic Pneumonia Panel Testing in Critically-ill Patients With Severe Hospital-acquired Pneumonia, Ventilator-associated Pneumonia and Community-acquired Pneumonia With High Risk of Multidrug Resistant Pathogen

An interventional study of Pneumonia Panel by FilmArray in Infectious Disease of Lung, Molecular Diagnosis and Pneumonia, sponsored by Mahidol University. Recruiting at 2 sites in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Mahidol University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the research is to ascertain the influence of a syndromic mutiplex PCR assay (FilmArray) on the management of patients hospitalised in the ICU for severe respiratory disease.

The diagnostic process for pneumonia has become significantly more intricate over the past decade due to the interference of the biological, radiological, and clinical criteria of patients hospitalised in the intensive care unit with the conventional criteria for the diagnosis of severe respiratory diseases. Additionally, patients who are hospitalised in the ICU are at a heightened risk of contracting other associated infections. Consequently, patients are frequently administered antibiotics, whether or not they are effective, as it is challenging to promptly determine the aetiology of their symptoms using conventional methods.

To enhance the diagnostic and therapeutic aspects of their treatment, we implemented a novel syndromic molecular test in our laboratories. This test is designed to expedite and enhance the management of pneumonia and the stewardship of antibiotics. This research will include 80 to 100 adult patients hospitalized in ICU between Feb 2025 and Feb 2027. It will take place within the Siriraj Hospital, Bangkok, Thailand.

Read the detailed description

Not provided

02

Conditions studied

  • Infectious Disease of Lung
  • Molecular Diagnosis
  • Pneumonia

Browse trials for

03

In context

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

This study's planned enrollment of 64 is below the median of 128 across 978 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients who have received complete information about the research and who have not objected to the use of its data
  • Patients with suspected pneumonia infection

Exclusion Criteria: Patients with following conditions;

  • Active immediate life-threatening cardiac arrhythmia, defined as ventricular tachycardia and ventricular fibrillation
  • Acute cerebral vascular event, including both acute ischemic stroke or intracranial hemorrhage Acute coronary syndrome
  • Cardiogenic shock
  • Life-threatening gastrointestinal hemorrhage
  • Drug overdose
  • Advanced-stage cancer with predicted survival less than 1 year
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Experimental: Pneumonia panel group

    Pneumonia panel measurement and changing of antimicrobials according to the result of pneumonia panel

    Diagnostic Test: Pneumonia Panel by FilmArray

  • No intervention
    No Intervention: Standard of care

    Standard practice

Interventions

  • Diagnostic testPneumonia Panel by FilmArray

    The Pneumonia Panel comprehensively identifies 33 potential pathogen targets from sputum-like (including endotracheal aspirate) and bronchoalveolar lavage (BAL)-like (including mini-BAL) samples. For 15 of the bacteria, the Pneumonia Panel provides semi-quantitative results, which may help determine whether an organism is a colonizer or a pathogen.

06

What researchers measure

Primary outcomes

  1. Therapeutic decision [Time Frame: 24 hours following the FilmArray results]

    Antibiotic prescription modification following the FilmArray results as: No prescription No change in antibiotic utilization Antibiotic initiation Antibiotic escalation Antibiotic de-escalation Antibiotic discontinuation

    Time frame: 24 hours following the FilmArray results

07

Study locations

1 of 2 sites recruiting
  • Siriraj Hospital
    Bangkok, Bangkok 10700, Thailand
    Recruiting
  • Siriraj Hospital, Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok, 10700, Thailand
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Publications

  • Stafylaki D, Maraki S, Vaporidi K, Georgopoulos D, Kontoyiannis DP, Kofteridis DP, Chamilos G. Impact of Molecular Syndromic Diagnosis of Severe Pneumonia in the Management of Critically Ill Patients. Microbiol Spectr. 2022 Oct 26;10(5):e0161622. doi: 10.1128/spectrum.01616-22. Epub 2022 Sep 26. PubMed 36154180 ↗
  • High J, Enne VI, Barber JA, Brealey D, Turner DA, Horne R, Peters M, Dhesi Z, Wagner AP, Pandolfo AM, Stirling S, Russell C, O'Grady J, Swart AM, Gant V, Livermore DM; INHALE Study Group. INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care-study protocol for a multicentre randomised controlled trial. Trials. 2021 Oct 7;22(1):680. doi: 10.1186/s13063-021-05618-6. PubMed 34620213 ↗
  • Kosai K, Akamatsu N, Ota K, Mitsumoto-Kaseida F, Sakamoto K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K. BioFire FilmArray Pneumonia Panel enhances detection of pathogens and antimicrobial resistance in lower respiratory tract specimens. Ann Clin Microbiol Antimicrob. 2022 Jun 4;21(1):24. doi: 10.1186/s12941-022-00512-8. PubMed 35659683 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 260 non-industry interventional studies with no phase under Pneumonia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 24 months is close to that.

Counting every sponsor, half of 267 studies reached it within 22 months; a quarter within 11 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 20, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added. Siriraj Hospital, Faculty of Medicine Siriraj Hospital, Mahidol University is now Active, not recruiting
Show site
  • Siriraj Hospital · Bangkok, Thailand
Nov 17, 2026
Enrollment
80→64
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added. Siriraj Hospital, Faculty of Medicine Siriraj Hospital, Mahidol University is now Active, not recruiting
    Show site
    • Siriraj Hospital · Bangkok, Thailand
    Enrollment 80→64
    + 5 other changes: identifiers, verification date, date precision, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06782607
Lead sponsor
Mahidol University
Responsible party
Adhiratha Boonyasiri (Assistant professor doctor, Mahidol University) — Principal investigator
First posted
Jan 20, 2025
Start date
Feb 1, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Adhiratha Boonyasiri, MD, MSc, PhD
Contact
adhiratha.bon@mahidol.ac.th
+664192688

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion